Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-07-23
The filing discloses the appointment of four officers to Fermi Inc. effective July 22, 2026: George Wentz as General Counsel, Anna Bofa as Chief Commercial Officer, Jacobo Ortiz as Chief Operating Officer, and Rob Masson as Chief Financial Officer. While the filing also includes compensatory arrangements (base salaries, bonuses, equity awards), the principal disclosed action centers on these individuals taking on executive roles. The appointments of a CFO and COO are material to a reasonable investor's assessment of the company's leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
Shaun McMeans was appointed as a Class III director of VASO Corporation effective July 23, 2026. The disclosure emphasizes his substantial public company finance and accounting experience, including prior service as CFO of HTG Molecular Diagnostics (2012–2023), and his appointment to the audit committee as a financial expert. Director appointments are material governance events affecting the composition and expertise of the board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
The filing discloses the appointment of Melissa Anastasiou as Chief Legal Officer of Sharon AI Holdings Inc., effective July 23, 2026. The press release (Exhibit 99.1) emphasizes her extensive background (20+ years in legal, finance, and governance; 16+ years at Spark New Zealand as Executive Group General Counsel) and her role in strengthening the executive leadership team. This is a material executive appointment to a named officer position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-23
The filing discloses two distinct executive events under Item 5.02: (1) appointment of David Allen to the Board of Directors and as Chair of the Audit Committee, and (2) approval of an employment agreement with Mark Heinen (CFO) including base salary, bonus structure, and severance terms. While both events are material, the appointment of a new independent director to the board and audit committee chair position is the primary disclosed action, making exec_appointment the most salient classification. The compensation arrangement with Heinen is secondary and supportive of the leadership continuity narrative.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-23
Item 5.02
The filing discloses both a director resignation (Michael Kosloske) and the appointment of a new director (Zebulon Z. Hadley, IV) to fill the vacancy. While both events are present, the principal action emphasized in the disclosure is the appointment of Hadley, including detailed biographical information, his appointment as Chair of the Compensation Committee, and confirmation of standard director compensation arrangements. The appointment of a new board member with significant business credentials and committee leadership is the salient event for investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
The filing discloses the appointment of Andre Mintz as a new director to CS Disco's board, effective immediately on July 22, 2026, increasing board size from eight to nine members. The disclosure includes his background, independence determination, and compensation arrangements (initial $300,000 RSU grant plus $35,000 annual cash retainer). This is a material governance event affecting board composition and investor assessment of the company's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
The Board appointed Michael Kappitt as a director effective July 24, 2026, expanding the Board from seven to eight members. This is a clear executive appointment event. While the disclosure also mentions standard director compensation, the principal action disclosed is the appointment of a new director with relevant restaurant industry experience (Chief Operating and Insights Officer at Subway, former President of Carrabba's Italian Grill). Board composition changes are material to investors assessing governance and leadership.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-23
The filing announces four new appointments to Santander UK's Executive Committee: Tom Ranger as CFO (effective 1 October 2026), Steve Affleck as Chief Accounting Officer (immediate effect), Michael Christodoulides as Chief Compliance Officer (effective 1 November 2026), and Iñaki Perkins as Head of Cards & Payments. While Angel Santodomingo's departure as CFO is also disclosed, the principal disclosed action is the appointment of these four executives to senior leadership roles. These are material C-suite appointments affecting the registrant's governance and strategic direction during the TSB integration.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
The filing discloses the election of two new directors, Katherine Fogertey and Scott Mezvinsky, to Valvoline's Board effective July 22, 2026. Both are appointed to specific Board committees (Audit and Governance & Nominating, respectively). This is a clear executive appointment event. While the disclosure also includes compensatory arrangements (pro-rated RSU awards of $70,644 each), the principal action is the appointment itself, making exec_appointment the most salient classification. The appointment of experienced executives from major public companies (Shake Shack CFO and KFC CEO) to the board is material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-23
EX-99.1
The press release announces the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO) of VERAXA Biotech AG, effective immediately. This is a named executive officer appointment to a C-suite role responsible for directing development of the company's proprietary BiTAC® platform technologies. The disclosure also notes the departure of the prior CSO, Rick Austin, Ph.D., but the principal disclosed action is Erkel's appointment to the CSO position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-23
Item 5.02
Three independent directors—Zhiqiang Du, Zhuo Liang, and Qian Xu—were appointed to the board effective July 21, 2026, in connection with the Company's Nasdaq listing, with assignments to audit and compensation committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
Joe DePinto was elected to Target's Board of Directors effective August 1, 2026, and appointed to the Audit & Risk Committee and Infrastructure & Finance Committee. This is a clear executive appointment of a director with significant retail and operational expertise (former 7-Eleven CEO). Board appointments of experienced executives are material to investors as they affect governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-22
Item 5.02
Edric C. Funk was elected President and Chief Executive Officer effective November 1, 2026, and immediately appointed to the Board of Directors. Richard M. Olson, the outgoing CEO, transitions to Executive Chairman. The filing also addresses compensation adjustments for both executives as part of this planned succession.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-22
Item 5.02
The filing discloses the appointment of Brent Stuart as Chief Executive Officer effective January 1, 2027, and his election to the Board effective July 22, 2026. While Rick Wessel's transition to Executive Chairman represents a departure from the CEO role, the principal disclosed action centers on Stuart's appointment to the CEO position and Board membership. This is a material executive succession event affecting the registrant's leadership structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-22
The 6-K discloses the Board of Directors' appointment of Manuel García Diez as Chief Financial Officer (CFO) of Telecom Argentina, effective August 3, 2026. This is a clear executive appointment of a named officer to a material C-suite position. CFO appointments are material to investors as they affect financial oversight and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-22
Item 5.02
Don W. Cummings was appointed Chief Executive Officer, President, and director effective October 1, 2026, with a compensation package of $1,050,000 base salary and $7,850,000 in long-term incentives. Brian M. Walta was simultaneously appointed Executive Vice President and Chief Financial Officer effective the same date with $600,000 base salary and $1,900,000 in long-term incentives. These appointments represent a material succession event affecting the company's top leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-22
Item 5.02
Jennifer M. Grigsby was elected to the Board of Directors on July 21, 2026, filling the vacancy created by Stephen Lee's resignation. Grigsby, a veteran public company director and energy finance executive with over 30 years of leadership experience, was appointed to serve as Chair of the Compensation Committee and member of the Nominating & Governance and Audit Committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
David C. Dennsteadt was named President and Chief Operating Officer effective July 17, 2026, with expanded responsibilities overseeing operating groups and leadership of strategy and corporate development.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-22
Item 5.02
Jeffrey Hanson appointed as permanent CEO (effective July 21, 2026) after serving as Interim CEO since February 2026; Gabe Willhite promoted to President and COO; and Scott Estes appointed Lead Independent Director. Danny Prosky retired from his CEO role as part of this leadership succession.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-22
Item 5.02
Four directors—Jeff Clarke, Raymond Bingham, David Golden, and Renée E. LaBran—were appointed to the Board of B&R Technology Merger Corp. effective July 20, 2026, in connection with the Company's IPO, with assignments to various board committees. This is a material governance event for the newly public SPAC.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-22
Item 5.02
Joseph Risico was appointed as a director to fill an existing Class I vacancy, and Ryan Daiss was appointed as President with detailed employment terms including base salary, performance bonuses, equity awards, and severance provisions.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-22
The 6-K discloses the appointment of Yu Guo as an independent director and chair of the audit committee on July 20, 2026, following the resignation of Jiahe Liao. While both a departure and appointment occur, the principal disclosed action is the appointment of a new director to fill the vacancy, making exec_appointment the primary classification. The appointment is material because it involves a change in board composition and audit committee leadership at a Nasdaq-listed company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-22
Item 5.02
The filing discloses both the resignation of CFO Polly Schneck and the appointment of John Boone as her successor, effective July 22, 2026. While both events occur, the disclosure centers substantively on Boone's appointment—his background, experience, and qualifications receive detailed treatment, whereas Schneck's departure is noted briefly as non-contentious. The appointment of a new CFO is material to investors assessing the company's financial leadership and operational continuity, particularly for a SPAC (NewHold Investment Corp IV) navigating post-IPO operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-22
Item 5.02
Susan Hunt was appointed as Chief Revenue Officer, effective July 17, 2026, to lead the Company's global revenue strategy and sales organization. Dr. Pouya Dianat transitioned from CRO to the newly created Chief Product Officer role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
Matthew Kreps was appointed to the Board of Directors of ASTROTECH Corp on July 16, 2026, increasing the board size from six to seven directors. Kreps brings extensive background in capital markets and investor relations, and received a restricted stock grant of 2,150 shares as part of his appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
AXT appointed Jia-Bin Duh as a Class III independent director effective July 16, 2026, expanding the Board from five to six members. Duh brings 30+ years of senior executive leadership at major technology companies (Hewlett-Packard, Microsoft, Cisco) and deep expertise in Greater China markets to support the company's subsidiary Tongmei and long-term growth strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
The filing discloses the appointment of Anuj Goel as Chief Financial Officer of SharonAI Holdings Inc., effective August 24, 2026. While the press release also mentions the departure of incumbent CFO Tim Broadfoot, the principal disclosed action centers on the appointment of a named executive to a C-suite officer role. The appointment is material as it affects the company's executive leadership during a growth phase.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-22
The filing discloses the appointment of Alexander Asgary as Chief Strategy Officer effective July 16, 2026, along with a concurrent consulting agreement providing $250,000 annual compensation plus $250,000 in warrant awards. While the filing also mentions Chris Chumas's transition to EVP of a subsidiary, the principal disclosed action centers on Asgary's appointment to a C-suite role with material compensation terms, making this an executive appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
The filing discloses the appointment of Mort Aaronson as a member of the Board of Directors on July 1, 2026, to fill a vacancy. The principal disclosed action is a person taking a role (board director), supported by detailed biographical information and the execution of a Director Agreement and Indemnification Agreement with specified compensation ($75,000 annually in shares). This is a clear executive appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The Board appointed Dr. Alexander Vollert as a director effective August 1, 2026. This is a clear executive appointment to the Board of Directors. While the disclosure notes that Guidewire recognized $11.3 million and $13.4 million in revenue from AXA SA (Dr. Vollert's former employer) during the relevant periods, the principal disclosed action is the appointment of a new director with significant operational and CEO experience at a major insurance company, which is material to investors assessing board composition and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-22
EX-99.1
The exhibit discloses the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026, with induction into the Management Council. This is a senior executive appointment that would materially affect investor assessment of the company's leadership and strategic direction in its biologics division. The secondary disclosure of the auditor appointment (Deloitte Haskins & Sells, LLP) is a routine auditor change that does not override the primary event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-07-22
EX-99.1
The Board approved on July 22, 2026, the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, with induction into the Management Council.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-22
Item 5.02
The filing discloses two executive transitions: Keith Regnante's resignation as CFO effective August 3, 2026, and Annita Tanini's appointment as interim principal financial officer and principal accounting officer effective August 4, 2026. While both events occur, the principal disclosed action centers on Tanini's appointment to the CFO role, including detailed compensation arrangements ($302,300 base salary, 30% bonus target, severance terms). The filing emphasizes her qualifications and new employment agreement, making the appointment the salient event, though Regnante's departure is also disclosed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The filing discloses the appointment of three new directors—Gemma Hemsworth, Fiona Callering, and Alistair Pemberton—to the Board of Directors of OXO, Inc., effective immediately on July 22, 2026. This is a clear executive appointment event under Item 5.02, as the principal disclosed action is persons taking board roles. Board composition changes are material to investors' assessment of governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The filing discloses the appointment of Farrell Simon, Pharm.D., to Serina's Board of Directors effective July 22, 2026, with concurrent appointment to the Audit and Compensation Committees. Dr. Simon brings significant commercial and business development expertise from his role as Chief Commercial Officer at Trevi Therapeutics and prior decade at Pfizer, making this a material governance event affecting board composition and oversight capabilities at a clinical-stage biotech company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-22
Item 5.02
The Board of Directors approved the appointment of Mark Jones, Jr., the Company's President and Chief Operating Officer, as CEO effective January 1, 2027, to succeed retiring CEO Mark Miller.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
The Board of Directors elected two new directors, David S. Marriott and Charles J. Meyers, effective July 20, 2026, and appointed them to specific board committees. This is a clear executive appointment event. While the disclosure also mentions standard non-employee director compensation, the principal action disclosed is the appointment of these two individuals to the Board, making this a material governance event affecting the composition of the company's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
The filing discloses the election of Octavio Marquez, president and CEO of Diebold Nixdorf, to MSA Safety's Board of Directors on July 20, 2026. This is a clear appointment of a director to the company's board, which is material to investors as board composition affects governance and strategic oversight. The disclosure explicitly states "the Board of Directors of MSA Safety Incorporated elected Octavio Marquez to the Company's Board of Directors" and notes his appointment was part of the board's regular succession plans.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
The filing discloses the election of David S. Schulz to Fulton Financial Corporation's board of directors, effective September 14, 2026, with appointment to the Audit and Risk committees. While the disclosure includes compensatory arrangements (pro rata RSU grant of $64,400), the principal disclosed action is the appointment of a director to the board. Schulz brings significant financial leadership experience from Wesco International and Armstrong World Industries, making this a material governance event affecting board composition and expertise.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
Bina Mehta was elected as an independent director of ExlService Holdings, effective July 16, 2026, with concurrent appointments to the Audit Committee and Compensation and Talent Management Committee.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-21
The 6-K discloses the appointment of Mr. Hung-Hsien Yen to the Board of Directors effective July 20, 2026, along with his committee assignments (Audit Committee member and Nominating and Corporate Governance Committee Chairman) and compensation terms. Although two directors also resigned on the same date, the principal disclosed action is the appointment of a new director with specified governance roles and equity/cash compensation arrangements, which is the hallmark of exec_appointment under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
James Beecham was appointed as a Class I Director to Aware Inc's Board of Directors on July 15, 2026, upon recommendation of the Nominating and Corporate Governance Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-21
Item 5.02
Jonathan E. Benfield was appointed Chief Financial Officer of CrossAmerica GP LLC, the general partner, effective immediately on July 20, 2026, transitioning from his interim role since March 2, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
Constantine Dakolias was appointed as a director and audit committee member of Bleichroeder Acquisition Corp. III effective July 20, 2026. The disclosure centers on the appointment of a qualified independent director with extensive investment and credit management experience, making this a clear executive appointment event material to investors evaluating the company's governance and board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-21
Item 5.02
The filing discloses the Board's nomination of Mr. Ng Tsze Lun for election as a director and his appointment as Chairman of the Board effective after stockholder approval at the 2026 annual meeting. While the filing also mentions Mr. Choi Lin Hung's decision not to stand for re-election as director and Chairman, the principal disclosed action centers on the appointment of Mr. Ng to the Chairman role. The press release reinforces this as a "Board Leadership Transition" with Mr. Ng succeeding Mr. Choi as Chairman, making the appointment the salient event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-21
The 6-K discloses the appointment of Mr. Nazario Matachione as a member of the Board of Directors of RoyaLand Company, Ltd. effective July 16, 2026. The filing explicitly states "the Board of Directors of The RoyaLand Company, Ltd. (the "Company") appointed Mr. Nazario Matachione as a member of the Board" and provides extensive biographical detail on his qualifications and experience. This is a clear executive appointment to the board, material to investors assessing the company's governance and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-21
Item 5.02
Getty Images appointed two new independent directors—Elizabeth Abrams and Thomas Walper—to its Board of Directors effective July 20, 2026. Ms. Abrams was also appointed to the Audit Committee, and both directors entered into independent director agreements providing monthly fees of $50,000 plus additional compensation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-21
Item 5.02
Three independent directors—Andrew Childs, Michael Westerman, and Karl Simich—were appointed to the board of AMR Resources Acquisition Corp. in connection with the IPO on July 16, 2026, with assignments to the Audit and Compensation Committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
Phio Pharmaceuticals appointed R. Todd Plott, M.D. to its Board of Directors effective July 20, 2026, increasing the board size to six members. Dr. Plott brings 30+ years of dermatologic experience and prior FDA advisory committee service, directly relevant to the company's clinical-stage development of PH-762 for skin cancers.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Dennis C. Schemm was elected to Blink Charging's Board of Directors effective July 19, 2026. The filing discloses his extensive financial and executive background, including current CFO role at FOX Factory and prior CFO positions at Trex Company and Continental Building Products. Board appointments of experienced executives with relevant expertise are material governance events affecting the registrant's leadership composition.
View raw filing on EDGAR →